PRECISION BIOSCIENCES INC — Director's Dealing 2019

Mar 27, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: PRECISION BIOSCIENCES INC (DTIL)
CIK: 0001357874
Period of Report: 2019-03-27

Reporting Person: YAO TONY DUNG LING (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Preferred Stock	$		Common Stock (4450)		Direct
Series B Preferred Stock	$		Common Stock (114570)		Indirect
Series B Preferred Stock	$		Common Stock (4450)		Indirect

Footnotes

F1: Each share of Series B Preferred Stock is convertible at the holder's election into approximately 0.468452971537734 share of the common stock of Precision BioSciences, Inc. (the "Issuer") (on an adjusted basis, after giving effect to the 1-for-2.134686 reverse stock split effected by the Issuer in connection with its initial public offering) and has no expiration date. The Series B Preferred Stock will automatically convert into common stock upon the closing of the Issuer's initial public offering.

F2: These securities are held of record by ArrowMark Life Science Fund, LP (the "ArrowMark Fund"), and ArrowMark Colorado Holdings LLC ("ArrowMark Colorado") is an investment advisor to the ArrowMark Fund. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the ArrowMark Fund. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.

F3: These securities are held of record by THB Iron Rose, LLC Life Science Portfolio (the "THB Fund"), and ArrowMark Colorado is an investment advisor to the THB Fund. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the THB Fund. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.